Brief: Calliditas Receives FDA Fast Track Designation For Setanaxib

Calliditas Therapeutics AB

09/08/2021 07:02

Aug 9 (Reuters) - Calliditas Therapeutics AB  CALTX.ST :
    * CALLIDITAS RECEIVES FDA FAST TRACK DESIGNATION FOR
SETANAXIB IN
PBC
    * HAS GRANTED FAST TRACK DESIGNATION (FTD) FOR ITS LEAD NOX
INHIBITOR CANDIDATE SETANAXIB FOR TREATMENT OF PATIENTS WITH
CHRONIC ORPHAN LIVER DISEASE PRIMARY BILIARY CHOLANGITIS
    * IS PLANNING TO INITIATE A PIVOTAL PHASE 2/3 STUDY IN PBC,
STARTING IN 2H 2021

Source text for Eikon:  ID:nWkr3SfGBJ 
Further company coverage:  CALTX.ST 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 772 0920;))